Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Investigational new drugs

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-013-9980-5PMID 23728919PMCID PMC4310688
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of erlotinib in patients with advanced Non‐small‐cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

  2012cited by this paper
• Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer

  2012cited by this paper
• Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.

  2010cited by this paper
• A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

  2010cited by this paper
• Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study

  2009cited by this paper
• A phase I study of vorinostat in combination with bortezomib in refractory solid tumors.

  2007cited by this paper
• Incorporating Bortezomib into the Treatment of Lung Cancer

  2007cited by this paper
• SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.

  2006cited by this paper
• Preclinical data with bortezomib in lung cancer.

  2005cited by this paper
• Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.

  2004cited by this paper

• Precision epigenetic therapies in oncology

  2025cites this paper
• Low-dose SAHA enhances CD8+ T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancer

  2024cites this paper
• Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis

  2023cites this paper
• Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence

  2023cites this paper
• miR-466 Contributes to the Enhanced Antitumor Effect of Bortezomib on Non-Small-Cell Lung Cancer by Inhibiting CCND1

  2022cites this paper
• The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention

  2022cites this paper
• Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

  2021cites this paper
• HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model.

  2020cites this paper
• Harnessing the vulnerabilities of p53 mutants in lung cancer – Focusing on the proteasome: a new trick for an old foe?

  2020cites this paper
• Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease

  2020cites this paper
• Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis.

  2019cites this paper
• Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer

  2018cites this paper
• Chromatin dynamics at the core of kidney fibrosis.

  2018cites this paper
• Epigenome-Based Precision Medicine in Lung Cancer.

  2018cites this paper
• Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas

  2018cites this paper
• Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.

  2018cites this paper
• Vorinostat enhances gefitinib‐induced

  2018cites this paper
• Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell

  2018cites this paper
• Role of epigenome in tumorigenesis and drug resistance.

  2017cites this paper
• Bronchial biopsy specimen as a surrogate for DNA methylation analysis in inoperable lung cancer

  2017cites this paper
• Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer

  2017cites this paper
• Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications.

  2016cites this paper
• Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines

  2016cites this paper
• Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results

  2015cites this paper
• HDAC Inhibitors: A New Radiosensitizer for Non-small-cell Lung Cancer

  2015cites this paper
• A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321

  2015cites this paper
• Epigenetic therapy in lung cancer and mesothelioma

  2015cites this paper
• Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model

  2015cites this paper
• Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

  2015cites this paper
• The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.

  2015cites this paper
• Epigenetic therapy for solid tumors: from bench science to clinical trials.

  2015cites this paper
• Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.

  2014cites this paper
• Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity

  2014cites this paper
• Potential role of histone deacetylase inhibitors in the treatment of advanced non-small-cell lung cancer

  2014cites this paper
• Trial Watch: Proteasomal inhibitors for anticancer therapy

  2014cites this paper
• Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update

  2014cites this paper
• Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells

  2014cites this paper
• A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)

  2013cites this paper